AU2001232735A1 - Process for solubilizing glucagon-like peptide 1 compounds - Google Patents

Process for solubilizing glucagon-like peptide 1 compounds

Info

Publication number
AU2001232735A1
AU2001232735A1 AU2001232735A AU3273501A AU2001232735A1 AU 2001232735 A1 AU2001232735 A1 AU 2001232735A1 AU 2001232735 A AU2001232735 A AU 2001232735A AU 3273501 A AU3273501 A AU 3273501A AU 2001232735 A1 AU2001232735 A1 AU 2001232735A1
Authority
AU
Australia
Prior art keywords
glp
solution
compound
compounds
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001232735A
Inventor
Walter Francis Junior Prouty
Joseph Vincent Junior Rinella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2001232735A1 publication Critical patent/AU2001232735A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Disclosed is a method of preparing a GLP-1 compound that is soluble in aqueous solution at pH 7.4 from a GLP-1 compound that is substantially insoluble in aqueous solution at pH 7.4. The insoluble GLP-1 compound is dissolved in aqueous base or in aqueous acid to form a GLP-1 solution. The GLP-1 solution is then neutralized to a pH at which substantially no amino acid racemization of the GLP-1 compounds occurs, after which the soluble GLP-1 compound is isolated from the neutralized solution.
AU2001232735A 2000-01-27 2001-01-16 Process for solubilizing glucagon-like peptide 1 compounds Abandoned AU2001232735A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17843800P 2000-01-27 2000-01-27
US60178438 2000-01-27
US22405800P 2000-08-09 2000-08-09
US60224058 2000-08-09
PCT/US2001/000010 WO2001055213A2 (en) 2000-01-27 2001-01-16 Process for solubilizing glucagon-like peptide 1 (glp-1) compounds

Publications (1)

Publication Number Publication Date
AU2001232735A1 true AU2001232735A1 (en) 2001-08-07

Family

ID=26874307

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001232735A Abandoned AU2001232735A1 (en) 2000-01-27 2001-01-16 Process for solubilizing glucagon-like peptide 1 compounds

Country Status (17)

Country Link
US (4) US7598222B2 (en)
EP (1) EP1257577B1 (en)
JP (1) JP2003523366A (en)
KR (1) KR20020073184A (en)
AT (1) ATE264870T1 (en)
AU (1) AU2001232735A1 (en)
BR (1) BR0107837A (en)
CA (1) CA2396920A1 (en)
DE (1) DE60102899T2 (en)
DK (1) DK1257577T3 (en)
ES (1) ES2218381T3 (en)
HU (1) HUP0204281A3 (en)
IL (2) IL150913A0 (en)
MX (1) MXPA02007231A (en)
PT (1) PT1257577E (en)
TR (1) TR200401142T4 (en)
WO (1) WO2001055213A2 (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ES2298378T3 (en) * 2001-06-28 2008-05-16 Novo Nordisk A/S STABLE FORMULATION OF MODIFIED GLP-1.
ES2500918T3 (en) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Albumin and interferon beta fusion proteins
ATE385193T1 (en) 2002-03-20 2008-02-15 Mannkind Corp INHALATION DEVICE
US7687625B2 (en) * 2003-03-25 2010-03-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2256189A1 (en) * 2003-03-28 2010-12-01 National Institute Of Agrobiological Sciences Process for producing a plant storage organ in which a GLP-1 derivative recombinant protein is highly produced.
ATE529126T1 (en) 2003-06-03 2011-11-15 Novo Nordisk As STABILIZED PHARMACEUTICAL PEPTIDE COMPOSITIONS
BRPI0410972C1 (en) 2003-06-03 2021-05-25 Novo Nordisk As method for increasing the shelf life of a pharmaceutical composition, pharmaceutical composition, and method for treating hyperglycemia
JP2007524592A (en) * 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー／エス Stabilized pharmaceutical peptide composition
US8921311B2 (en) 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
RU2006107553A (en) * 2003-08-13 2007-09-20 Такеда Фармасьютикал Компани Лимитед (Jp) 4-Pyrimidone derivatives and their use as peptidyl peptidase inhibitors
WO2005030751A2 (en) * 2003-09-08 2005-04-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005026148A1 (en) * 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
HUE043210T2 (en) * 2003-11-20 2019-08-28 Novo Nordisk As Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
CN102134230B (en) * 2004-03-15 2019-06-28 武田药品工业株式会社 Depeptidyl peptidase inhibitors
AU2005277208B2 (en) 2004-08-20 2011-11-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
DK1791542T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte for pharmaceutical delivery
WO2006024631A2 (en) * 2004-08-31 2006-03-09 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
CA2586771A1 (en) 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of insulinotropic peptides
US7601423B2 (en) 2004-11-19 2009-10-13 Mitsui Chemicals, Inc. Ethylene-based polymer microparticles, functional group-containing ethylene-based polymer microparticles, and catalyst carriers for manufacture thereof
EP2805953B1 (en) 2004-12-21 2016-03-09 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006069779A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
TW200643033A (en) * 2005-03-08 2006-12-16 Chugai Pharmaceutical Co Ltd Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
JP5252915B2 (en) 2005-04-07 2013-07-31 三井化学株式会社 Capsule-shaped fine particles made of olefin polymer
BRPI0615819B8 (en) 2005-09-14 2021-05-25 Mannkind Corp process for preparing a drug delivery composition comprising an active agent and a crystalline fumaryl diketopiperazine microparticle.
RS52110B2 (en) * 2005-09-14 2018-05-31 Takeda Pharmaceuticals Co Dipeptidyl peptidase inhibitors for treating diabetes
HRP20140091T4 (en) * 2005-09-14 2021-12-24 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
WO2007033265A1 (en) * 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetis
CN101360723A (en) * 2005-09-16 2009-02-04 武田药品工业株式会社 Process for the preparation of pyrimidinedione derivatives
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
CN101379075B (en) 2006-02-08 2013-05-15 隆萨股份公司 Synthesis of glucagon-like peptide
CN101389348A (en) 2006-02-22 2009-03-18 曼金德公司 A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
WO2007112368A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
BRPI0716971A2 (en) * 2006-09-13 2013-10-15 Takeda Pharmaceutical USE OF 2-6 (3-AMINO-PIPERINI-L-IL) -3-METHYL-2,4-DIOXO-3,4-DIHYDRO-2 H-PYRIMIDIN-1YLMETHYL-4-FLUORO-BENXONITRIL
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
CA3086027C (en) 2008-06-13 2022-05-17 Mannkind Corporation A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
MX2010014240A (en) 2008-06-20 2011-03-25 Mankind Corp An interactive apparatus and method for real-time profiling of inhalation efforts.
TWI532497B (en) 2008-08-11 2016-05-11 曼凱公司 Use of ultrarapid acting insulin
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2379100T3 (en) 2009-01-08 2014-12-01 Mannkind Corp Treatment of hyperglycemia with GLP-1
DK2405963T3 (en) 2009-03-11 2013-12-16 Mannkind Corp DEVICE, SYSTEM AND PROCEDURE FOR MEASURING RESISTANCE IN AN INHALATOR
WO2010144789A2 (en) 2009-06-12 2010-12-16 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
WO2011017554A2 (en) * 2009-08-07 2011-02-10 Mannkind Corporation Val (8) glp-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
KR20130117755A (en) 2010-06-21 2013-10-28 맨카인드 코포레이션 Dry powder drug delivery system and methods
CN102718858B (en) * 2011-03-29 2014-07-02 天津药物研究院 Glucagon-like peptide-1 (GLP-1) analogue monomer and dimer, preparation method therefor and application thereof
WO2012135765A2 (en) 2011-04-01 2012-10-04 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
MX2014004983A (en) 2011-10-24 2014-09-22 Mannkid Corp Methods and compositions for treating pain.
CN104619369B (en) 2012-07-12 2018-01-30 曼金德公司 Dry-powder medicament induction system and method
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
ES2624961T3 (en) 2013-03-21 2017-07-18 Sanofi-Aventis Deutschland Gmbh Synthesis of peptide products containing cyclic imide
CN105189465B (en) 2013-03-21 2019-02-26 赛诺菲-安万特德国有限公司 Synthesize the peptide prod containing hydantoins
JP6491658B2 (en) 2013-07-18 2019-03-27 マンカインド コーポレイション Thermally stable dry powder pharmaceutical composition and method
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US9969769B2 (en) 2014-12-19 2018-05-15 Cem Corporation Coupling method for peptide synthesis at elevated temperatures
US10308677B2 (en) 2014-12-19 2019-06-04 Cem Corporation Coupling method for peptide synthesis at elevated temperatures
CN109715662B (en) 2015-12-23 2023-07-21 美国安进公司 Methods of treating or ameliorating metabolic disorders using combinations of GIPR binding proteins and GLP-1 agonists
JOP20190177A1 (en) 2017-01-17 2019-07-16 Amgen Inc Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
AU2018321157B2 (en) 2017-08-24 2024-03-28 Novo Nordisk A/S GLP-1 compositions and uses thereof
WO2019120480A1 (en) 2017-12-19 2019-06-27 Novo Nordisk A/S Solubility of glp-1 peptide
WO2019200594A1 (en) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 Acylated glp-1 derivative
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As Glp-1 compositions and uses thereof
WO2022157747A2 (en) 2021-01-25 2022-07-28 Mylan Ireland Limited Pharmaceutical peptide compositions and methods of preparation thereof
WO2022266927A1 (en) * 2021-06-24 2022-12-29 深圳翰宇药业股份有限公司 Liraglutide variant, preparation method therefor, and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3419824A1 (en) * 1984-05-26 1985-11-28 Bayer Ag, 5090 Leverkusen METHOD AND MOLDING TOOL FOR PRODUCING MOLDED PARTS WITH GRILL, GRID OR RUST-LIKE AREAS, LIKE VEHICLE SOFT FACES, SPOILERS, BUMPER, FROM A FLOWABLE DIMENSION
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US6384016B1 (en) * 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
US6844321B2 (en) * 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue

Also Published As

Publication number Publication date
IL189371A0 (en) 2008-06-05
HUP0204281A3 (en) 2007-03-28
DE60102899T2 (en) 2005-03-31
US20130072658A1 (en) 2013-03-21
DK1257577T3 (en) 2004-08-02
ATE264870T1 (en) 2004-05-15
PT1257577E (en) 2004-08-31
US8222205B2 (en) 2012-07-17
CA2396920A1 (en) 2001-08-02
US8455433B2 (en) 2013-06-04
US20030060412A1 (en) 2003-03-27
IL150913A0 (en) 2003-02-12
WO2001055213A2 (en) 2001-08-02
HUP0204281A2 (en) 2003-04-28
US20110053838A1 (en) 2011-03-03
EP1257577B1 (en) 2004-04-21
TR200401142T4 (en) 2004-07-21
ES2218381T3 (en) 2004-11-16
BR0107837A (en) 2003-01-14
MXPA02007231A (en) 2002-12-09
EP1257577A2 (en) 2002-11-20
KR20020073184A (en) 2002-09-19
US8268780B2 (en) 2012-09-18
US7598222B2 (en) 2009-10-06
JP2003523366A (en) 2003-08-05
US20120208980A1 (en) 2012-08-16
WO2001055213A3 (en) 2002-02-28
DE60102899D1 (en) 2004-05-27
US20120101034A9 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
AU2001232735A1 (en) Process for solubilizing glucagon-like peptide 1 compounds
EP2272825A3 (en) N-Protected amino hydroxy adamantane carboxylic acid and process for its preparation
DE69030100D1 (en) PEPTIDE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING IT
WO2000071125A3 (en) Pharmaceutical preparation containing the active substance diamorphine and its utilization in a method for treating opiate addiction
AU2093100A (en) Recovery of a protein at high ph
WO2002051979A3 (en) Method to remove citrate and aluminum from proteins
DK1150999T3 (en) Cyclosporin derivatives and process for their preparation
EP0296581A3 (en) Amino acid 1,2-diketo derivatives as renin inhibitors
ID21224A (en) METHOD OF MAKING DRUGS CONTAINING PROTEIN PLASMA
ATE322891T1 (en) DRUG DELIVERY SYSTEM FOR WATER-SOLUBLE DRUGS
IT1319674B1 (en) PROCESS FOR THE PREPARATION OF CYCLOHEXANACETIC ACID1- (AMINOMETHYL).
AU4770400A (en) Fused polycyclic amino acids as pharmaceutical agents
HK1047093A1 (en) Process for production of naphthyridine-3-carboxyrlic acid derivatives.
MXPA03008837A (en) A stable pharmaceutical composition of pravastatin.
CY1106051T1 (en) PROCESS FOR THE PRODUCTION OF N-PROTECTED AZETIDINO-2-CARBOXYLIC ACIDS (AzeOHs)
WO2000073540A8 (en) Method for producing a cyanide-free solution of a gold compound that is suitable for galvanic gold baths
FR2788271B1 (en) NEW PROCESS FOR THE PREPARATION OF CHIRAL AMINO ACIDS
MY119965A (en) Process for preparing methylene bisphosphonic acids and salts thereof.
TW347383B (en) A process for the production of a crystalline sodium salt of amoxicillin in ethanol as solvent
EP1065199A3 (en) "Process for the recovery of strong acids from aqueous solution"
EP1398316A3 (en) Process for the preparation of 1,3-Dihydro-6-methylfuro(3,4-c)pyridin-7-ol Derivatives
MXPA05006279A (en) Process for the preparation of pregnanes.
DE60105216D1 (en) Process for the preparation of aromatic acylthiocarboxylic acid derivatives
WO2002062355A3 (en) Hydriodic acid and iodide salts for treatment of male impotence
BG103923A (en) Sulphate salt of hiv protease inhibitor with improved peroral absorption and biopresence